Table 3. Summary of vasodilator perfusion CMR validation publications.
Year | First author | n | Excluded | Stress | Reference | Sensitivity | Specificity |
2007 | Merkle et al70 | 228 | 0 | Adenosine | Cath >50% | 93 | 86 |
2006 | Ingkanisorn et al54 | 141 | 4 | Adenosine | Prognosis | 100 | 93 |
2006 | Klem et al58 | 92 | 3 | Adenosine | Cath >70% | 89 | 87 |
2006 | Pilz et al63 | 176 | 5 | Adenosine | Cath >70% | 96 | 83 |
2006 | Rieber et al66 | 50 | 7 | Adenosine | Cath >50% and FFR | 88 | 90 |
2005 | Okuda et al60 | 33 | 0 | Dipyridamole | Cath >70% | 84 | 87 |
2005 | Plein et al65 | 92 | Adenosine | Cath >70% | 88 | 82 | |
2005 | Sakuma et al67 | 40 | 0 | Dipyridamole | Cath >70% | 81 | 68 |
2004 | Bunce et al50 | 35 | 0 | Adenosine | Cath >50% | 74 | 71 |
2004 | Giang et al52 | 94 | 14 | Adenosine | Cath >50% | 93 | 75 |
2004 | Kawase et al56 | 50 | 0 | Nicorandil | Cath >70% | 94 | 94 |
2004 | Paetsch et al61 | 49 | 0 | Adenosine | Cath >75% | 89 | 80 |
2004 | Paetsch et al62 | 79 | Adenosine | QCA >50% | 91 | 62 | |
2004 | Plein et al64 | 72 | 4 | Adenosine | Cath >70% | 88 | 83 |
2004 | Takase et al69 | 102 | 0 | Dipyridamole | Cath >50% | 93 | 85 |
2003 | Doyle et al51 | 199 | 15 | Dipyridamole | Cath >70% | 78 | 82 |
2003 | Ishida et al55 | 104 | 0 | Dipyridamole | Cath >70% | 84 | 82 |
2003 | Kinoshita et al57 | 27 | Dipyridamole | Cath >75% | 55 | 77 | |
2003 | Nagel et al59 | 90 | 6 | Adenosine | Cath >75% | 88 | 90 |
2002 | Ibrahim et al53 | 25 | Adenosine | QCA >75% | 69 | 89 | |
2001 | Schwitter et al68 | 48 | 1 | Dipyridamole | QCA >50% | 85 | 94 |
2000 | Al-Saadi et al49 | 40 | 6 | Dipyridamole | Cath >75% | 90 | 83 |
CMR, cardiovascular magnetic resonance.